Health & Safety Industry Today

Introduction of new drugs, and therapeutic options are majorly driving the growth of Crohn’s disease Market at about 4% CAGR by 2022

Market Research Future published a Half cooked research report on “Global Crohn’s Disease Market Research Report - Forecast to 2022” – Market Analysis, Scope, Stake, Progress, Trends and Forecast to 2022.
Published 11 December 2017
Crohn's disease is a chronic inflammatory bowel disorder that often leads to surgery for most with the disease. According to researchers with the U.S. Centers for Disease Control and Prevention, hospitalization rates for the Crohn’s disease grew 4% each year, from 1998 to 2004, however, post that, there has been drastic change in the hospitalization rates and researchers found it fairly stable since then till 2013. Well, thanks to the new drugs, biosimilars and therapeutic options that are now available in the market.

Get a sample report at https://www.marketresearchfuture.com/sample_request/2344 .

According to a recent study report published by the Market Research Future analysts, the global Crohn’s Disease market is currently very dynamic and growing at a moderate pace. This growth is mainly due to introduction of the novel therapies and new drugs into the market. Earlier, the market for Crohn’s disease was fairly dominated by drugs such as adalimumab (Humira), infliximab (Remicade), certolizumab (Cimzia) etc. However, entry of Entyvio (vedolizumab), interleukin (IL)-12/23 inhibitor, and Stelara (ustekinumab) has made an impactful attempt to extricate the stronghold of the TNF inhibitors, as they aim to tap into the lucrative segment of Crohn’s Disease therapeutics.
Experts say, exciting times are ahead for the Crohn’s Disease market, as the market events noted above are due to occur against the backdrop of a steadily growing Crohn’s Disease prevalent population. With the clinical unmet need for better diagnostic tools and treatment options for the anti-TNF-refractory population, Crohn’s Disease remains an attractive autoimmune disease for drug developers.

Global Crohn’s Disease Market - Competitive Analysis
The global Crohn’s Disease market is well established market with large number of drugs and therapies available in the market. There are large number of companies involved in the development of the drugs which are now widely used all across the world for the treatment of Crohn’s Disease and some for ulcerative colitis, and rheumatoid arthritis as well.
One of the major development in this market is the patent expiry for the current market leaders. The patent expiry began back in 2015. The loss of patent protection of the anti-TNF marketed brands has allowed for the emergence of biosimilars, such as Hospira’s Inflectra (infliximab) a Remicade biosimilar. There are great developments happening in CD therapeutics space.

Browse Complete Report at https://www.marketresearchfuture.com/reports/crohns-disease-market-2344 .

In May 2017, AbbVie announced positive Phase 2 study results for Upadacitinib (ABT-494), an investigational JAK1-Selective Inhibitor, in Crohn's disease.
In April 2017, Samsung Bioepis Co., Ltd. announced that the U.S. Food and Drug Administration (FDA) has approved Renflexis (infliximab-abda), a biosimilar referencing Remicade (infliximab). In the US, Renflexis is indicated for reducing signs and symptoms in patients with adult and pediatric Crohn’s disease.
In November 2016, AbbVie received orphan drug designation for investigational IL-23 Inhibitor Risankizumab from the U.S. Food and Drug Administration for the treatment of pediatric patients with Crohn's Disease.
In October, 2016 Allergan plc entered into licensing agreement with AstraZeneca to obtain worldwide rights of MEDI2070 for the development of the potential treatment of Crohn's Disease and Ulcerative Colitis.

Ask Question to Expert at https://www.marketresearchfuture.com/enquiry/2344 .

Americas commanded the market with the largest market share in 2016 and Americas is expected to continue to be the largest market for the Crohn’s Disease during the forecasted period 2017 to 2022. This large share is majorly attributed to the presence of large number of CD drug manufacturers in the United States. Also there have been recent FDA approvals for the drugs to be used in United States for the Crohn’s disease and ulcerative colitis. Development of biosimilars by the companies like Abbvie have greatly boosted the U.S. market for Crohn’s Disease. European market is not far behind and is slowly catching up with the American market. With advent of novel therapies, Europe, the CD therapeutic business has grown significantly in the region. Asia Pacific region is quickly accepting the changing trend of therapeutic approach and it is expected to be the fastest growing region in the Crohn’s disease market during the forecasted period 2017 to 2022.

 About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact
Market Research Future
P: +1 646 845 9312
W: www.marketresearchfuture.com
sales@marketresearchfuture.com
 

Other Industry News

Ready to start publishing

Sign Up today!